| Symbol | MYGN |
|---|---|
| Name | MYRIAD GENETICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Address | 322 NORTH 2200 WEST, SALT LAKE CITY, UT 84116 |
| Telephone | 801-584-3600 |
| Fax | — |
| — | |
| Website | https://www.myriad.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000899923 |
| Description | Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individuals risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. Additional info from NASDAQ: |
2026-07-02 13:05
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Read more
2026-06-23 20:25
Director Skovronsky Daniel 🟡 adjusted position in 0 shares of MYRIAD GENETICS INC (MYGN) Transaction Date: Jun 23, 2026 | Filing ID: 044911
Read more
2026-06-23 13:05
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Read more
2026-06-12 22:06
Director Raha Samraat S. 🟢 acquired 3.5K shares of MYRIAD GENETICS INC (MYGN) at $3.94 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read more
2026-06-12 22:05
Donnelly Brian J 🟢 acquired 5.0K shares of MYRIAD GENETICS INC (MYGN) at $3.94 Transaction Date: Jun 11, 2026 | Filing ID: 000006
Read more
2026-06-09 20:20
Director Kumar Rashmi 🔴 sold 15.0K shares of MYRIAD GENETICS INC (MYGN) at $4.46 Transaction Date: Jun 08, 2026 | Filing ID: 000004
Read more
2026-06-08 15:17
📋 Kumar Rashmi (Director) plans to sell 15K shares of MYRIAD GENETICS INC (at $4.59 each, total $69K) Filed: Jun 08, 2026 | ID: 004408
Read more
2026-06-05 20:25
Director Skovronsky Daniel 🟢 acquired 59.7K shares of MYRIAD GENETICS INC (MYGN) Transaction Date: Jun 04, 2026 | Filing ID: 041258
Read more
2026-06-05 20:25
Director Newcomer Lee Nisley 🟢 acquired 59.7K shares of MYRIAD GENETICS INC (MYGN) Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07052266 | Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | Na | Hereditary Cancer Syndromes | Recruiting | 2025-09-02 | 2028-12-01 | ClinicalTrials.gov |
| NCT05642780 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Phase2 | Solid Tumor | Active_Not_Recruiting | 2023-01-17 | 2027-12-31 | ClinicalTrials.gov |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patient… | Phase4 | Metastatic Castration-resistant Prostate Cancer | Active_Not_Recruiting | 2022-07-29 | 2026-12-31 | ClinicalTrials.gov |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients'… | Phase1 | Pancreatic Adenocarcinoma Metastatic | Recruiting | 2021-01-13 | 2028-12-01 | ClinicalTrials.gov |
| NCT04245176 | Genetic Testing for All Breast Cancer Patients (GET FACTS) | Na | Breast Cancer | Completed | 2020-01-31 | 2026-01-01 | ClinicalTrials.gov |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Rel… | Phase3 | Non-Germline BRCA Mutated Ovarian Cancer | Completed | 2018-01-30 | 2022-03-10 | ClinicalTrials.gov |
| NCT03150810 | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combin… | Phase1 | Locally Advanced or Metastatic Solid Tumors | Completed | 2017-06-28 | 2023-05-04 | ClinicalTrials.gov |
| NCT03081455 | Impact of a Process Intervention on Screening and Testing Outcomes for Common H… | — | Hereditary Cancer | Completed | 2017-02-13 | 2017-08-04 | ClinicalTrials.gov |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men… | Phase3 | Metastatic Castration-resistant Prostate Cancer | Completed | 2017-02-06 | 2023-02-15 | ClinicalTrials.gov |
| NCT02773004 | Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision… | Na | Breast Cancer | Completed | 2016-09-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Ad… | Phase3 | Ovarian Neoplasms | Active_Not_Recruiting | 2016-07-11 | 2026-05-29 | ClinicalTrials.gov |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or… | Phase2 | Ovarian Neoplasms | Completed | 2015-03-23 | 2021-08-23 | ClinicalTrials.gov |
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensi… | Phase1 | Ovarian Cancer | Completed | 2015-02-15 | 2021-12-15 | ClinicalTrials.gov |
| NCT03076242 | Genetic Evaluation of Men (GEM) | — | Prostate Cancer | Terminated | 2014-10-23 | 2019-05-16 | ClinicalTrials.gov |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed Hig… | Phase3 | Ovarian Cancer | Completed | 2014-04-07 | 2022-07-07 | ClinicalTrials.gov |
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | Phase2 | Triple Negative Breast Cancer | Completed | 2014-04-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade … | Phase2 | Ovarian Cancer | Completed | 2013-10-30 | 2021-09-28 | ClinicalTrials.gov |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sen… | Phase3 | Ovarian Neoplasms | Completed | 2013-06-21 | 2021-12-26 | ClinicalTrials.gov |
Total clinical trials: 18
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | COMPLETED | NCT04245176 |
| GEM Registry | Other | Preclinical | Prostate Cancer | TERMINATED | NCT03076242 |
| Diagnostic Test | Other | Preclinical | Hereditary Cancer | COMPLETED | NCT03081455 |
| Bevacizumab | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02354131 |
| Niraparib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02354131 |
| Niraparib | Other | Phase PHASE2 | Ovarian Neoplasms | COMPLETED | NCT02354586 |
| placebo | Other | Phase PHASE3 | Ovarian Neoplasms | COMPLETED | NCT01847274 |
| Active comparator: Niraparib | Other | Phase PHASE3 | Ovarian Neoplasms | COMPLETED | NCT01847274 |
| Placebo | Other | Phase PHASE3 | Ovarian Cancer | COMPLETED | NCT01968213 |
| Rucaparib | Other | Phase PHASE3 | Ovarian Cancer | COMPLETED | NCT01968213 |
| Oral rucaparib | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT01891344 |
| EPClin genomic test | Other | Approved | Breast Cancer | COMPLETED | NCT02773004 |
| abiraterone acetate | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02987543 |
| enzalutamide | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02987543 |
| olaparib | Other | Phase PHASE3 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT02987543 |
| Olaparib | Other | Phase PHASE3 | Non-Germline BRCA Mutated Ovarian Cancer | COMPLETED | NCT03402841 |
| Temozolomide | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT03150810 |
| Pamiparib | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT03150810 |
| Quantitative Genetic Counseling | Other | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04245176 |
| Standard Genetic Counseling | Other | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04245176 |
| Pembrolizumab | Other | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05642780 |
| SKB264 | Other | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05642780 |
| Paclitaxel | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT01982448 |
| Cisplatin | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT01982448 |
| MyRisk Hereditary Cancer Test | Other | Approved | Hereditary Cancer Syndromes | RECRUITING | NCT07052266 |
| Autologous Hematopoietic Stem Cells | Other | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Vitamin C | Other | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Vitamin B12B | Other | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| BCNU | Other | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Melphalan | Other | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Placebo | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT02655016 |
| Niraparib | Other | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT02655016 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| Prednisone | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| abiraterone acetate | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| enzalutamide | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| olaparib | Other | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT05457257 |
| MyRisk Hereditary Cancer Test | GENETIC | Approved | Hereditary Cancer Syndromes | RECRUITING | NCT07052266 |
| Pembrolizumab | DRUG | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05642780 |
| SKB264 | DRUG | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05642780 |
| Prednisone | DRUG | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT05457257 |
| Quantitative Genetic Counseling | BEHAVIORAL | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04245176 |
| Standard Genetic Counseling | BEHAVIORAL | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04245176 |
| Autologous Hematopoietic Stem Cells | DEVICE | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Vitamin C | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Vitamin B12B | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| BCNU | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Melphalan | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma Metastatic | RECRUITING | NCT04150042 |
| Olaparib | DRUG | Phase PHASE3 | Non-Germline BRCA Mutated Ovarian Cancer | COMPLETED | NCT03402841 |
| Temozolomide | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT03150810 |
| Pamiparib | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | COMPLETED | NCT03150810 |
| GEM Registry | OTHER | Preclinical | Prostate Cancer | TERMINATED | NCT03076242 |
| abiraterone acetate | DRUG | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT05457257 |
| enzalutamide | DRUG | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT05457257 |
| olaparib | DRUG | Phase PHASE4 | Metastatic Castration-resistant Prostate Cancer | COMPLETED | NCT05457257 |
| EPClin genomic test | OTHER | Approved | Breast Cancer | COMPLETED | NCT02773004 |
| Bevacizumab | DRUG | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02354131 |
| Niraparib | DRUG | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT02655016 |
| Placebo | DRUG | Phase PHASE3 | Ovarian Neoplasms | ACTIVE_NOT_RECRUITING | NCT02655016 |
| Rucaparib | DRUG | Phase PHASE3 | Ovarian Cancer | COMPLETED | NCT01968213 |
| placebo | DRUG | Phase PHASE3 | Ovarian Neoplasms | COMPLETED | NCT01847274 |
| Active comparator: Niraparib | DRUG | Phase PHASE3 | Ovarian Neoplasms | COMPLETED | NCT01847274 |
| Paclitaxel | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT01982448 |
| Cisplatin | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT01982448 |
| Oral rucaparib | DRUG | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT01891344 |
Total products: 113